CAS: 112457-95-1; Tandospirone Citrate

该化合物是指一种复杂的有机化合物,其特征是多环结构和功能组.该物质与六氢结构结合,表明各种立体化学结构的饱和潜力.存在一种管状动物运动表明潜在的药效性活动,因为经常在生物活性化合物中发现管状物.此外,列入一个火合胺环可能增强它与生物目标的相互作用,特别是在药用化学中.三碳基酸组表示存在多种卡本酸组,能够影响溶性和药理化合物的再生变动力,

英文名称Tandospirone Citrate
中文名称枸橼酸坦度螺酮
IUPAC名称2-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)butyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione 2-hydroxypropane-1,2,3-tricarboxylate
CAS编号112457-95-1
MFCD编号:MFCD01939743
FDA UNII编号:0R8E9BWM4J
分子式:C21H29N5O2.C6H8O7
分子量:575.615
产品CID: 157740
同类组份化合物CAS87760-53-0 (free base)99095-10-0 (HCl)112457-95-1 (citrate)
产品分类原料药 → 神经系统用药

相似结构搜索
产品信息参考;;
InChIKey: DMLGUJHNIWGCKM-DPFKZJTMSA-N
DMLGUJHNIWGCKM-DPFKZJTMNA-N…
计算化学: 氢键受体数14.0氢键供体数4.0可旋转键数11.0

物理性质

熔点169.5-170°
沸点613.9 °C at 760 mmHg
闪点325.1 °C
PSA:201.77
LogP:0.1022
蒸汽压5.23E-15mmHg at 25°C
溶解性Water: 10.4 mg/mL (18.07 Mm)
外观形态白色至类白色固体
储存条件惰性气氛,存放于冰箱中, -20°C
产品应用该化合物是5-HT1A受体部分刺激剂,显示有选择性超过5HT2,5H-T1C,Α1,Α2,D1和D2受体,在5HT吸收点,5-HT1B,Β-肾脏,肌肉催化和苯并二氮杂卓受体不活动,显示不氧活动.

MSDS等安全信息

合成工艺路线路线简述

合成目标产物 Tandospirone Citrate 主要起始原料 Tandospirone And Citric Acid
(文献来源)合成步骤主要原料 Tandospirone 和 Citric Acid

海关参考信息

2905122000-异丙醇
2905143000-叔丁醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-11459325-B2
优先权日:2018-01-31
标题:Heterocyclic compound
发明人：TANAKA YUTA; OHASHI TOMOHIRO; IKEDA ZENICHI; TANAKA YUTA; PÃœNNER FLORIAN; YAMAMOTO TAKESHI; KAKEGAWA KEIKO; KIKUCHI FUMIAKI; MORISHITA NAO; KASAHARA TAKAHITO; SETO MASAKI; NAKAMURA MINORU; TAKAMI KAZUAKI; MURAKAMI MASATAKA; DAINI MASAKI; MIKAMI SATOSHI; SASAKI MINORU
权利人:TAKEDA PHARMACEUTICALS CO
摘要:The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. n The present invention relates to a compound represented by the formula (I): n nwherein each symbol is as described in the specification, or a salt thereof.